Three-drug combo for advanced myeloproliferative cancers
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a combination of three drugs (pacritinib, venetoclax, and azacitidine) in people whose myeloproliferative neoplasm (MPN) has progressed to a faster-growing, more aggressive phase (accelerated or blast phase). The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an MPN (like essential thrombocythemia, polycythemia vera, or primary myelofibrosis) that has advanced to accelerated or blast phase.
- Your white blood cell count must be less than 25 before starting treatment (or can be lowered with medication or a procedure first).
- You cannot have had certain other treatments, like venetoclax, navitoclax, or a stem cell transplant for blast phase disease.
- Your liver and kidney function must be adequate, as shown by blood tests.
- You must not have active, serious infections or other uncontrolled medical conditions.
- You must not be pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether venetoclax together with azacitidine can shrink and control advanced blood cancers caused by myeloproliferative neoplasms (MPN) that do not have the BCR-ABL gene. It may help people whose disease has moved into an accelerated or blast phase when standard options haven’t yet included blast-reducing treatment.
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
This trial tests adding pacritinib to standard hypomethylating agents (azacitidine or decitabine) before a stem cell transplant for people with myeloproliferative neoplasms (MPN) that have progressed to a more advanced phase.
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
This trial tests a combination of two drugs (pacritinib and talazoparib) for people with certain bone marrow cancers that have not responded well to standard JAK2 inhibitor therapy. The goal is to see if this combination can help shrink the spleen, improve symptoms, or slow disease progression.
This trial tests a drug called pacritinib for people with CMML. It's for those who haven't had JAK inhibitor therapy before and may have had only one cycle of other treatments.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.